Genmab announces ofatumumab Phase III study in follicular lymphoma to be stopped following planned interim analysis

Genmab A/S has announced that the Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin’s lymphoma (NHL) that has relapsed at least… Source link